Compare PTLO & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTLO | IMRX |
|---|---|---|
| Founded | 1963 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.4M | 340.7M |
| IPO Year | 2021 | 2021 |
| Metric | PTLO | IMRX |
|---|---|---|
| Price | $5.79 | $5.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $8.06 | ★ $17.20 |
| AVG Volume (30 Days) | ★ 1.3M | 766.3K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $732,066,000.00 | N/A |
| Revenue This Year | $9.02 | N/A |
| Revenue Next Year | $5.81 | N/A |
| P/E Ratio | $24.17 | ★ N/A |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $4.41 | $1.10 |
| 52 Week High | $13.55 | $10.08 |
| Indicator | PTLO | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 47.18 |
| Support Level | $5.27 | $5.31 |
| Resistance Level | $6.09 | $5.36 |
| Average True Range (ATR) | 0.33 | 0.37 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 28.69 | 16.98 |
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.